Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

Syndax Pharmaceuticals (SNDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kelly ...

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...

In recent trading, Syndax Pharmaceuticals Inc (SNDX) stock price has shown some volatility, fluctuating -27.42% over the last five trades and -20.41% over the past 30 trades. This represents a notable ...

Syndax (SNDX) Pharmaceuticals announced that the U.S. FDA has approved Revuforj as the first and only menin inhibitor for the treatment of relapsed or refractory acute leukemia with a lysine ...

Syndax Pharmaceuticals (NASDAQ:SNDX) just reported positive results from the phase 2 portion of its AUGMENT-101m trial evaluating the use of Revumenib for the treatment of patients with relapsed ...

"The data being presented this year at ASH demonstrate Syndax's commitment to develop revumenib as a practice-changing therapy for adult and pediatric patients with acute leukemias," said Neil ...

Syndax Pharmaceuticals , Inc. (NASDAQ:SNDX) is a biotechnology company focused on developing innovative cancer therapies. With recent FDA approvals and upcoming regulatory decisions, Syndax is ...